Qiagen N.V. Stock 12‑Month Price Target Raised to $47.43, Implies 7% Upside

QIAGEN reported that BlackRock holds 11.54% capital interest and 12.91% voting rights in the company as of October 5, 2026, according to a Dutch AFM notification.

Barclays upgraded QIAGEN (QGEN) to Overweight from Equalweight. The stock has a 5-day change of +2.32% and a year-to-date change of +1.73%. The upgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

Qiagen (QGEN) shares rose 7.3% on reports of advanced acquisition talks with a U.S. molecular testing company. The company is reportedly undervalued by 10% with a GF Value of $49.93. Private equity firms TPG Inc. and Bain Capital have shown interest. Qiagen's GF Score is 76/100, indicating strong valuation and profitability but moderate growth.

Qiagen's shares rose 7.3% on reports that acquisition talks with potential buyers have advanced. Traders cited a Betaville alert, while Manager Magazin previously reported interest from TPG, Bain Capital, KKR, EQT, and Advent. The company is working with Moelis & Co. and Goldman Sachs on its strategic review.

Qiagen (QGEN) shares rose 7.3% on reports that talks with a US-listed molecular testing company have progressed, potentially leading to an acquisition at a 'realistic premium.'

Qiagen's QIAstat-Dx BCID GN Plus AMR Panel, cleared by the FDA, detects 13 gram-negative bacteria and 18 antibiotic resistance markers in about an hour. The test complements the previously cleared gram-positive and fungal panel, offering rapid bloodstream infection identification. Qiagen aims to support timely treatment decisions and address antibiotic resistance, with the QIAstat-Dx system available in over 100 countries.